ACHC Stock Analysis: Acadia Healthcare | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 2.935m USD | 12M Return: 26.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 81.7M
EPS Trend: -89.7%
Qual. Beats: 1
Rev. Trend: 98.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) is a U.S.-based behavioral healthcare services provider that owns and operates a diversified network of facilities, including acute inpatient psychiatric hospitals, residential recovery and eating disorder treatment centers, comprehensive treatment centers, residential treatment centers, and outpatient behavioral health programs. Founded in 2005 and headquartered in Franklin, Tennessee, the company serves communities across the United States and Puerto Rico, operating under a capital-intensive, facility-based business model typical of the healthcare facilities sub-industry, which is subject to extensive state and federal licensing and reimbursement regulations.
- Patient admission recovery drives same-store revenue growth
- Labor cost inflation pressures operating margins
- New facility openings accelerate revenue expansion
| Net Income: -1.11b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -1.03 > 1.0 |
| NWC/Revenue: 10.32% < 20% (prev 5.25%; Δ 5.07% < -1%) |
| CFO/TA 0.03 > 3% & CFO 182.0m > Net Income -1.11b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.9m) vs 12m ago -1.28% < -2% |
| Gross Margin: 56.21% > 18% (prev 62.53%; Δ -6.32% > 0.5%) |
| Asset Turnover: 57.65% > 50% (prev 51.34%; Δ 6.31% > 0%) |
| Interest Coverage Ratio: -6.22 > 6 (EBIT TTM -920.4m / Interest Expense TTM 148.0m) |
| A: 0.06 (Total Current Assets 837.2m - Total Current Liabilities 489.4m) / Total Assets 5.55b |
| B: -0.14 (Retained Earnings -761.7m / Total Assets 5.55b) |
| C: -0.16 (EBIT TTM -920.4m / Avg Total Assets 5.85b) |
| D: 0.58 (Book Value of Equity 1.96b / Total Liabilities 3.38b) |
| Altman-Z'' = -0.49 = B |
| DSRI: 1.10 (Receivables 547.7m/468.0m, Revenue 3.37b/3.16b) |
| GMI: 1.11 (GM 62.53% / 56.21%) |
| AQI: 0.67 (AQ_t 0.27 / AQ_t-1 0.40) |
| SGI: 1.07 (Revenue 3.37b / 3.16b) |
| TATA: -0.23 (NI -1.11b - CFO 182.0m) / TA 5.55b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 31.28 with a total of 2,906,275 shares traded. Over the past week, the price has changed by -1.97%, over one month by +30.82%, over three months by +20.59% and over the past year by +26.69%.
Current recommended Stop Loss: 29.60 (which is 5.4% or 1.2 ATR below the current price).
Acadia Healthcare has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ACHC.
- StrongBuy: 7
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 28.9 | -7.7% |
P/E Forward = 21.2766
P/S = 0.8705
P/B = 1.4986
P/EG = 1.3745
Revenue TTM = 3.37b USD
EBIT TTM = -920.4m USD
EBITDA TTM = -725.8m USD
Long Term Debt = 2.49b USD (from longTermDebt, last quarter)
Short Term Debt = 54.3m USD (from shortTermDebt, last quarter)
Debt = 2.81b USD (from shortLongTermDebtTotal, last quarter) + Leases 143.2m
Net Debt = 2.65b USD (calculated: Debt 2.81b - CCE 158.5m)
Enterprise Value = 5.59b USD (2.93b + Debt 2.81b - CCE 158.5m)
Interest Coverage Ratio = -6.22 (Ebit TTM -920.4m / Interest Expense TTM 148.0m)
EV/FCF = -19.16x (Enterprise Value 5.59b / FCF TTM -291.8m)
FCF Yield = -5.22% (FCF TTM -291.8m / Enterprise Value 5.59b)
FCF Margin = -8.66% (FCF TTM -291.8m / Revenue TTM 3.37b)
Net Margin = -32.84% (Net Income TTM -1.11b / Revenue TTM 3.37b)
Gross Margin = 56.21% ((Revenue TTM 3.37b - Cost of Revenue TTM 1.48b) / Revenue TTM)
Gross Margin QoQ = 16.53% (prev 11.68%)
Tobins Q-Ratio = 1.01 (Enterprise Value 5.59b / Total Assets 5.55b)
Interest Expense / Debt = 5.26% (Interest Expense 148.0m / Debt 2.81b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -727.1m (EBIT -920.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.71 (Total Current Assets 837.2m / Total Current Liabilities 489.4m)
Debt / Equity = 1.44 (Debt 2.81b / totalStockholderEquity, last quarter 1.96b)
Debt / EBITDA = -3.66 (negative EBITDA) (Net Debt 2.65b / EBITDA -725.8m)
Debt / FCF = -9.10 (negative FCF - burning cash) (Net Debt 2.65b / FCF TTM -291.8m)
Total Stockholder Equity = 2.53b (last 4 quarters mean from totalStockholderEquity)
RoA = -18.93% (Net Income -1.11b / Total Assets 5.55b)
RoE = -43.82% (Net Income TTM -1.11b / Total Stockholder Equity 2.53b)
RoCE = -18.33% (EBIT -920.4m / Capital Employed (Equity 2.53b + L.T.Debt 2.49b))
RoIC = -14.68% (negative operating profit) (NOPAT -727.1m / Invested Capital 4.95b)
WACC = 6.86% (E(2.93b)/V(5.75b) * Re(9.46%) + D(2.81b)/V(5.75b) * Rd(5.26%) * (1-Tc(0.21)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -33.33 | Cagr: -0.49%
[DCF] Fair Price = unknown (Cash Flow -291.8m)
EPS Correlation: -89.71 | EPS CAGR: -19.93% | SUE: 1.91 | # QB: 1
Revenue Correlation: 98.66 | Revenue CAGR: 6.79% | SUE: 0.39 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.36 | Chg30d=-2.27% | Revisions=-29% | Analysts=13
EPS next Quarter (2026-09-30): EPS=0.48 | Chg30d=-0.15% | Revisions=-29% | Analysts=13
EPS current Year (2026-12-31): EPS=1.51 | Chg30d=+0.41% | Revisions=+17% | GrowthEPS=-24.6% | GrowthRev=+2.9%
EPS next Year (2027-12-31): EPS=1.75 | Chg30d=+0.84% | Revisions=+17% | GrowthEPS=+16.1% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: -12% (up=6, down=8)